On February 24, 2022 Xspray Pharma AB (publ), (Nasdaq Stockholm: XSPRAY) reported an update on recent developments regarding Xspray Pharma’s first product, Dasynoc, currently under review by the United States Food & Drug Administration ("FDA") (Press release, Xspray, FEB 24, 2022, View Source [SID1234650013]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Bristol Myers Squibb ("BMS") has filed a lawsuit in the United States District Court for the District of New Jersey against Xspray Pharma claiming patent infringement in relation to the filing of Xspray Pharma’s Dasynoc New Drug Application ("NDA") with the FDA.

"Xspray Pharma has a process for making stable amorphous products that are not covered by BMS’s patents. While we cannot predict the outcome of any litigation, BMS’s lawsuit is entirely expected, and I am confident the court will ultimately rule in our favor and allow us to provide an improved product", said Per Andersson, CEO Xspray Pharma.

The ongoing work with Dasynoc remains on track and these developments will not mean any change of strategic or operational direction for Xspray Pharma. It is also worth noting that the ongoing FDA approval process will proceed in parallel.

Xspray Pharma will not be providing any additional information or comments on this matter for the time being.